Navigation Links
ChemoCentryx President and CEO, Thomas J. Schall, Ph.D., Named Ernst & Young Entrepreneur Of The Year 2010 Award Finalist in Northern California
Date:5/19/2010

MOUNTAIN VIEW, Calif., May 19 /PRNewswire/ -- ChemoCentryx, Inc., today announced that Thomas J. Schall, Ph.D., the Company's President and Chief Executive Officer is a finalist for the Ernst & Young Entrepreneur Of The Year® 2010 Award in Northern California.  According to Ernst & Young LLP, the awards program recognizes entrepreneurs who demonstrate extraordinary success in the areas of innovation, financial performance and personal commitment to their businesses and communities.  Dr. Schall was selected as a finalist from over 100 nominations by a panel of independent judges.  Award recipients will be announced at a special gala event on June 12, 2010, at the San Jose Fairmont Hotel.

Dr. Schall is being recognized for his role in founding and leading ChemoCentryx, a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer.  As one of the earliest investigators in the field of chemokine biology, Dr. Schall and his team at ChemoCentryx have successfully established one of the broadest pipelines of chemokine-based therapeutics in the pharmaceutical industry, with five products now in clinical development.

"I am honored to be included in such a prestigious program," said Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx.  "It has been an extremely rewarding experience to work with this gifted ChemoCentryx team to build the Company and help bring us closer to providing valuable new treatment options for patients who suffer from autoimmune and
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ChemoCentryx Demonstrates Recently Discovered Chemokine Receptor CXCR7 is Essential in Tumor Growth
2. ChemoCentryx Advances Second Orally Available CCR9 Antagonist CCX025 Into Clinical Development
3. ChemoCentryx Identifies Novel Small Molecule C5aR Antagonist
4. ChemoCentryxs Traficet-EN(TM) Phase II/III Induction Phase Data in Crohns Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week
5. KGI Names Kerry Howell Vice President for Advancement
6. Vical Names Andrew de Guttadauro Vice President, Corporate Development
7. Emisphere Technologies, Inc. Appoints Paul Lubetkin as Vice President and General Counsel
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
10. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
11. CryoLife Names Philip Theodore as Vice President, General Counsel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 iLab Solutions, the leader in core ... Director of Product Strategy. In this role, Michelle will work ... to guide in the development of iLab products. Her main ... possible benefit to the scientific community by offering the most ...
(Date:1/14/2014)... Mass. , Jan. 14, 2014  RXi Pharmaceuticals ... discovering, developing and commercializing innovative therapies addressing major ... that it received the Notice of Allowance from ... its unique self-delivering RNAi compounds (sd-rxRNA®), for the ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... ) and sales and operations planning ( S&OP ) service, ... Biomanufacturing Summit , which will be held at the Hilton ... conference, join Kinaxis customer Elisabeth Kaszas , Director of ...
(Date:1/14/2014)... January 14, 2014 Kerr Corporation, a leading ... and additional how-to information about dual arch impressions on its ... Dual Arch Impressions,” the blog entry serves up a list ... houses a step-by-step demonstration by Dr. David Little as he ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2
... Caliper Life Sciences, Inc. (NASDAQ: CALP ... an innovative sequencing service provider based in Gaithersburg, Md. ... 5500xl, SOLiD 4, and Ion Torrent Personal Genome Machine ... initially focus on sample preparation for exome, whole genome, ...
... EMERYVILLE, Calif., June 27, 2011 MedeAnalytics, a ... announced the launch of its Patient Access Resource ... the front end of the revenue cycle, the ... performance indicators and industry trends, as well as ...
... 2011 Mediabrands, IPG Media Lab and Affectiva ... Festival, the results of the first annual Neuromarketing ... able to record and measure viewers, tacit, non-verbal ... individual,s facial features are established and are then ...
Cached Biology Technology:EdgeBio Selects Caliper's Sample Preparation Suite for High Throughput and Benchtop Sequencing Workflows 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3
(Date:4/17/2014)... a word for chili peppers. Information about archaeological remains ... study of the appearance of words for chili peppers ... were domesticated and highlight the value of multi-proxy data ... al.) of nine papers presented in a special feature ... of Sciences on plant and animal domestication edited ...
(Date:4/17/2014)... Luca Razzari of the nergie Matriaux Tlcommunications Research ... the John R. Evans Leaders Fund of the ... of state-of-the-art biotech and nanophotonics equipment. To this ... Ministre de l,Enseignement suprieur, de la Recherche, de ... new laboratories will help us develop new approaches ...
(Date:4/17/2014)... University engineer has developed a patented technique that ... devices. The same technique could help police during ... and Kay L. Theede chair in engineering and ... his research team have created a template-based system ... trunks. The distance detection method called stand-off ...
Breaking Biology News(10 mins):Chickens to chili peppers 2Chickens to chili peppers 3New state-of-the-art biotech and nanotech equipment for INRS 2Patented research remotely detects nitrogen-rich explosives 2
... honey bees? How can the spread of the deadly ... enemy? Could the olive fruit fly be similarly controlled? ... what exactly is the Bagrada bug? Entomologists from the ... bug-related questions at a conference on Sept. 19 at the ...
... University and the American Museum of Natural History has ... opposite sides of the Indian Ocean are each other,s ... that these eyeless fishes, one group from Madagascar and ... from a common ancestor before being separated by continental ...
... of a specific mutation in a gene in horses that ... strongly related to racing performance and is advantageous for harness-racing ... impact on their diversification, as the altered gait characteristics of ... a study that includes a Texas A&M University researcher. ...
Cached Biology News:Eyeless Australian fish have closest relatives in Madagascar 2Eyeless Australian fish have closest relatives in Madagascar 3Controlling gait of horses may be possible, says key study from Texas A&M 2
Homo sapiens similar to Cytosolic acyl coenzyme A thioester hydrolase Antigen: Peptide...
Borrelia Burgdorfen (IgG) -Ab EIA Sample Size: 100 l...
96 Well Base Plate...
... ANTI-RNase is a protein ribonuclease inhibitor that noncovalently ... No inhibition is seen with RNase 1, T1, ... distinct from human placental ribonuclease inhibitor in that ... and does not release active RNase in the ...
Biology Products: